Keryx Biopharma (KERX) Misses Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Price: $3.36 --0%
Financial Fact:
Basic and diluted net loss per common share: -0.39
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Basic and diluted net loss per common share: -0.39
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Keryx Biopharma (NASDAQ: KERX) reported Q4 EPS of ($0.32), $0.07 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $8.41 million.
For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Reservoir Media, Inc. (RSVR) Tops Q2 EPS by 2c; offers guidance
- Datadog stock tumbles 19% despite earnings beat
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
